NATTO: OPTIONS GRANTED
Based on the power of attorney granted at the annual general meetings of NattoPharma ASA ("NattoPharma" or "Company") on May 20th, 2016, the Board of Directors of NattoPharma has in board proceedings July 21st, 2016 granted a total of 312 500 options to management, key employees and strategic partners.
The following persons have been granted options;
|Name||Position / Function||Granted Options||Options prior to grant||Options after grant|
|Daniel H Rosenbaum||CEO||75.000||0||75.000|
|Eric Anderson||SVP Global Sales & Marketing||25.000||0||25.000|
|Rudi de Man||VP Sales & Marketing Europe & Asia||25.000||0||25.000|
|William Sommer||VP Global Development and Regulatory||25.000||0||25.000|
|Laura Bakker||Finance Manager||12.500||0||12.500|
|Mike Dornish||Strategic Partner||12.500||0||12.500|
The options have an exercise price equal the volume weighted average price the 10 last trading days as of July 21st 2016, which is equal to NOK 9,16.
The options granted are vested immediately, and may be exercised up to and including March 31st 2018.
* * *
For more information, please contact:
Kjetil Ramsøy, Chief Financial Officer
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.